Drug Discovery World

MARCH 12, 2024

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. This is part of a series of predictions based on different themes.

Molecular Biology 204

Molecular Biology Small Molecule Therapies FDA Approval 204

Drug Discovery World

MAY 1, 2024

DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Artificial intelligence (AI) AI is on everyone’s minds as we head into 2024; of course, this is across not just the drug discovery spectrum but is particularly relevant to therapeutic antibodies.

FDA Approval 147

FDA Approval Therapies FDA Molecular Biology 147

Drug Discovery World

MARCH 12, 2024

These confounding factors limit the opportunity for big pharma, especially considering the poor access to the complex small molecule pharmacophores known to have a link to the target disease and from which drug discovery programmes can be rolled out. RA: Could you discuss the concept of new-to-nature?

Small Molecule 147

Small Molecule Synthetic Chemistry Production Molecular Biology 147

Drug Discovery World

DECEMBER 26, 2023

We are excited to enter into this partnership with Shionogi, a company sharing the same patient centric values as Sobi and look forward to launching cefiderocol from 2024.” Dr Isaac Chan, an Assistant Professor in UT Southwestern’s Departments of Internal Medicine and Molecular Biology, will be the primary advisor for the collaboration.

Small Molecule 130

Small Molecule Drugs Molecular Biology Bioinformatics 130

Drug Discovery World

APRIL 30, 2024

It’s worth noting that the approach of small molecules interacting with mRNA biology represents a relatively new and potentially broader and more effective strategy. At the start of 2024, the first patients in a clinical trial investigating an mRNA cancer therapy were dosed. Sig Transduct Target Ther 2022;7:166.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Elrig

APRIL 29, 2024

Fascinated by the potential of AI in medical research, I transitioned to BenevolentAI in early 2023 as a Biology Project Leader. There, I supported AI-enabled DD efforts in their small molecule portfolio. Joining Isomorphic Labs in October 2024, I’m thrilled to be part of their mission to revolutionize DD through AI/ML.

Bioinformatics 59

Bioinformatics Molecular Biology Drugs Cell Based Assays 59

Drug Target Review

FEBRUARY 15, 2024

Advances in molecular biology have led to highly safe, efficient, and effective platforms, such as mRNA, that can be rapidly re-purposed for different pathogens, multiple pathogens, or new strains of evolving pathogens. 2023 [cited 2024 Jan 22]. 2023 [cited 2024 Jan 22]. 2019 [cited 2024 Jan 22]. 29, 2023] | U.S.

Drug Development 121

Drug Development Virus Vaccine Government 121